Article Details
Retrieved on: 2024-07-27 10:17:18
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA granting RMAT designation to Kyverna Therapeutics' KYV-101, a CAR T-cell therapy, for treating refractory stiff-person syndrome. This highlights advancements in regenerative medicine involving gene therapy and immunotherapy. Tags: 'Food and Drug Administration, Pharmaceuticals policy, Pharmacy, Regenerative Medicine Advanced Therapy, Gene therapy, CAR T cell, Stiff-person syndrome, Immunotherapy, Cytokine release syndrome, Kyverna Therapeutics Inc.'
Article found on: www.neurologylive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here